Treprostinil Pregnancy and Breastfeeding Warnings
Treprostinil Pregnancy Warnings
Treprostinil has been assigned to pregnancy category B by the FDA. Studies in rats have failed to reveal evidence of fetotoxicity or teratogenicity. An increased incidence of fetal skeletal variations associated with maternal toxicity were reported in rabbit studies (at 41 times the human starting dose). There are no controlled data in human pregnancy. Treprostinil is only recommended for use during pregnancy when benefit outweighs risk.
Treprostinil Breastfeeding Warnings
There are no data on the excretion of treprostinil into human milk. The manufacturer recommends that caution be used when administering treprostinil to nursing women.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.